Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials
Moderate FT was reported at baseline and on trial among EPCT participants. No change in FT was observed between time points. Additional efforts should be made to decrease FT associated with EPCT participation to maximize access to novel therapies.
Authors
- Olivia Hapanowicz
- Gabriela Fazilov (ORCID: https://orcid.org/0000-0002-5668-1015)
- Deborah B. Doroshow (ORCID: https://orcid.org/0000-0002-2221-9818)
- Cardinale B. Smith (ORCID: https://orcid.org/0000-0003-3635-8701)
- Matthew D. Galsky (ORCID: https://orcid.org/0000-0001-7655-9378)
- Mandy DeMerchant
- G. B. Shelton
- Joseph P. Eder (ORCID: https://orcid.org/0000-0002-7805-0986)
- Kathy Wu
- Jiahua Lu (ORCID: https://orcid.org/0000-0001-8544-891X)
- Suzanne Xu (ORCID: https://orcid.org/0000-0001-9389-8953)
- Melanie Wain Kier (ORCID: https://orcid.org/0000-0001-8209-0414)
- Thomas U. Marron (ORCID: https://orcid.org/0000-0001-5903-8191)
- Patricia LoRusso (ORCID: https://orcid.org/0000-0001-7144-036X)
- Natalie Lucas
- Michael Lachowicz
- Julia Blanter (ORCID: https://orcid.org/0000-0002-2682-5719)
- Erin Hofstatter (ORCID: https://orcid.org/0000-0002-0908-8841)
- Grace Van Hyfte (ORCID: https://orcid.org/0009-0001-8791-2285)
- Michael Werner (ORCID: https://orcid.org/0009-0008-3183-4426)
- Maham Ahmad
Institutions
- Northwell Health (US)
- Hofstra University (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Yale Cancer Center (US)
- Yale University (US)
- GlaxoSmithKline (India) (IN)
- Arvinas (United States) (US)
- Ribon Therapeutics (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1200/op.24.00293
- Citations
- 1
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Cancer Research Institute
- Conquer Cancer Foundation
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Regeneron Pharmaceuticals
- Celldex Therapeutics
- Five Prime Therapeutics
- Atara Biotherapeutics
- Mersana Therapeutics
- Veracyte
- Relay Therapeutics
- Actuate Therapeutics
- Compass Therapeutics
- UroGen Pharma
- G1 Therapeutics
- Glenmark Pharmaceuticals
- Seagen
- Astellas Pharma
- Genentech
- EMD Serono
- National Cancer Institute